- Home
- SOGP vs ADXN Comparison
SOGP vs ADXN Comparison
Compare SOGP & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOGP
- ADXN
- Stock Information
- Founded
- SOGP 2010
- ADXN 2002
- Country
- SOGP Singapore
- ADXN Switzerland
- Employees
- SOGP N/A
- ADXN N/A
- Industry
- SOGP
- ADXN Biotechnology: Pharmaceutical Preparations
- Sector
- SOGP
- ADXN Health Care
- Exchange
- SOGP NYSE
- ADXN Nasdaq
- Market Cap
- SOGP 6.9M
- ADXN 8.1M
- IPO Year
- SOGP 2020
- ADXN N/A
- Fundamental
- Price
- SOGP $4.30
- ADXN $9.00
- Analyst Decision
- SOGP
- ADXN Strong Buy
- Analyst Count
- SOGP 0
- ADXN 1
- Target Price
- SOGP N/A
- ADXN $30.00
- AVG Volume (30 Days)
- SOGP 1.9M
- ADXN 10.6K
- Earning Date
- SOGP 07-07-2025
- ADXN 06-19-2025
- Dividend Yield
- SOGP N/A
- ADXN N/A
- EPS Growth
- SOGP N/A
- ADXN N/A
- EPS
- SOGP N/A
- ADXN 0.10
- Revenue
- SOGP $278,363,908.00
- ADXN $278,508.00
- Revenue This Year
- SOGP $48.88
- ADXN $86.57
- Revenue Next Year
- SOGP N/A
- ADXN N/A
- P/E Ratio
- SOGP N/A
- ADXN $0.72
- Revenue Growth
- SOGP N/A
- ADXN N/A
- 52 Week Low
- SOGP $1.18
- ADXN $6.51
- 52 Week High
- SOGP $4.81
- ADXN $13.27
- Technical
- Relative Strength Index (RSI)
- SOGP 73.35
- ADXN 55.39
- Support Level
- SOGP $3.71
- ADXN $8.02
- Resistance Level
- SOGP $4.48
- ADXN $9.78
- Average True Range (ATR)
- SOGP 0.61
- ADXN 0.73
- MACD
- SOGP 0.27
- ADXN 0.02
- Stochastic Oscillator
- SOGP 84.40
- ADXN 32.94
About SOGP SOUND GROUP INC SPON ADS EA REP 200 ORD SHS(POST SPLIT)
Sound Group Inc is a world-wide audio-centric social and entertainment company. It Leverages broad product portfolio and in-house technologies, Sound Group caters to user interest in audio entertainment and social networking. Sound Group nurtures a globally diverse and inclusive team, drawing on talent from various countries and regions world-wide.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.